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Abstract  
Introduction: AEFIs underreporting is one of different barriers to achieving objectives of pharmaco vigilance of vaccine worldwide. Studies 
describe it as being related to limited awareness of health personnel and of vaccinees or of their parents. The objective was to assess the effect of 
telephone "beep" on community based reporting rates of AEFIs during routine immunization sessions in a Cameroon Health District. Methods: It 
was a randomized control trial implemented during routine EPI in Biyem-Assi health district (Cameroon). Parents of vaccinated children were 
randomly assigned: i) to receive the telephone contact of the investigation team and was advised to ''beep''(short phone call not picked up) the 
investigators team in the case any medical incidence occurs within the 30 days following the immunization (intervention group) or; ii) to return to 
the health facility in case any medical incidence occurs within the same period (control group). The main outcome was AEFI incidence rate. 
Results: 236 parents were assigned to the intervention group and 235 to the control group. Of 1192 doses of EPI vaccines administered, 20 AEFIs 
(392 AEFIs/100000 doses/week) were reported within 30 days after vaccine administration. These included 19 (829 AEFIs/100000 doses/week) 
AEFIs in the intervention group and 1 (43 AEFIs/100000 doses/week) AEFI in the control group. The AEFIs reporting rate in the intervention group 
was significantly higher than that in the control group [RR = 18.9; CI95 (2.5; 140.0) (P=0.0004)]. Conclusion: The use of telephone "beep" 
significantly increases at affordable cost community based AEFI reporting rate in routine EPI. 
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Introduction 
 
Adverse events following immunization (AEFI) surveillance is a 
recommendation for the Expanded Program on Immunization (EPI) 
at national and international levels [1-5]. However it is limited due 
to low reporting rate, often explained by many reasons [6-8]. The 
situation is more serious in the developing countries due to limited 
resources, geographical and cultural inaccessibility to health facilities 
[9-11]. Health facility based AEFI detection and reporting by health 
personnel is currently recommended in the Cameroon national EPI 
SOPs [12]. However, AEFI reporting forms are rarely filled and 
transmitted through the right channel as required. This situation has 
not yet been investigated but may can be explained by weakness of 
the surveillance system and inaccessibility of health facilities to 
populations due to lack of awareness, enclave and believes of the 
population [11- 16]. Several strategies have been tested to improve 
the AEFI detection and reporting rates including standardized health 
facility supervision [17] and SMS reminder [17- 20].In a study in 
Cameroon, 451 health facilities were randomly assigned to receive 
either weekly standardized “short message service” (sms) text 
messages or a weekly standardized supervisory visits or no 
intervention for four weeks after immunization campaign. 
Furthermore, a study in Australia for five months a cohort of 3,047 
pregnant women who received the 2013 trivalent influenza vaccine 
(TIV)) provided mobile telephone numbers and were sent sms 
inquiring whether they had experienced an AEFI [18]. Moreover, in 
another study in the united states (US), for 19 months 3226 adults 
and parents of paediatric patients who received routine vaccination 
were sent an sms by smart vax, a prototypic active monitoring 
system for AEFI, inquiring whether they had experience an AEFI 
[19]. Though beneficial to an extent, their effectiveness is limited 
since certain strategies had no significant effect or no control 
strategy. Besides, all these strategies are very costly strategy is 
needed to ensure universal benefit. We believed that using 
telephone “beep” is less costly and would increase reporting rate of 
AEFI, higher than the reporting rate of the routine AEFI surveillance 
activities. This study was conducted to assess during routine 
immunization in a health district in Cameroon, the effect of 









An ethical approval was obtained from the national ethics committee 





This was a randomized controlled field trial. Parents meeting 
inclusion criteria were randomly assigned to receive (i) a telephone 
contact of the investigation team and was advised to call back in the 
case any medical incidence occurs within the 30 days following the 
immunization or (ii) was advised as routinely recommended to 
return to the health facility in case any medical event occurs during 
the indicated period. The primary outcome was the incidence of 
AEFI per 100 parents per month reported. Informed consent of all 
participants was obtained after the procedure and objective of the 




The study targeted parents coming with their children for 
vaccination to the district hospital of Biyem-Assi-Yaoundé, these 
parents were eligible for the study. Inclusion criteria for parents in 







Mobile phone signal or “beep”: Parents in the interventional group 
received a telephone contact of the investigation team and advised 
to call back in the case any medical event occurs within 30 days 




Parents in the control group receive the routine advice as required 
to come back in the health facility in case any event occurs during 
the indicated period after immunization 
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Outcome 
  
The primary outcome was the incidence of AEFI per 100 parents per 
month reported during intervention period. The numerator being the 
sum of detected and reported AEFI and the denominator the 
number of parents multiplied by the number of month of follow-up. 
Information concerning the telephone number of parents, the age, 





Sample size calculation was based on the test of null hypothesis that 
there is no difference between telephone “beep” usage on AEFI 
reporting rate compared to returning to the health facility as 
routinely advised. The level of significance was set at 0.05. The 
sample size was calculated using the Oxford university press 
publications on methods for field trial interventions against tropical 
diseases. Assuming telephone “beep” increases reporting to 
50%,with the relative reporting rate ratio (RR) as 1.5.To account for 




A restrictive randomization was used. It was an allocation with a 
block size of two and two interventions named A and B. Therefore, 
four allocation sequences were possible (AA, AB, BA, BB). Each 
allocation sequence was numbered from one to four and using a 
table of random numbers, for each 2 participants, a number was 
randomly selected to choose the appropriate sequence. The random 
allocated sequence was generated by the principal investigator; the 
enrollment and assignation of participants were done by the 
investigation team (principal investigator and two master students in 
public health).Blinding here was not necessary because the study 




The incidence rate of reported AEFI was estimated per study group 
and measured by estimating the number of AEFI detected and 
reported per 100parents per month. The effect or the difference in 
reporting rates in the both groups were estimated by calculating the 
relative incidence rate (RR) .The chi-squared test permitted us to 
compare reporting rates and the p value indicated the significance 
of the effect (degree of significance fixed at 5%). All analysis was 





Recruitment and participants flow 
  
From the 23/12/2013 up to the 23/01/2014 a total of the 509 
parents were asked to participate to the study 38(7.4%) were 
excluded; reason for exclusion was essentially absence of cell 
phone. A total of 471 (92.5%) parents were included and assigned 
to each of the two groups, 236(50.1%) and 235 (49.8%) in the 
interventional and control group respectively. The same proportions 
received intended interventions and were analyzed for AEFI 
reporting. Figure 1 shows the enrollment and assignment of 
participants in the flow. The vaccine against poliomyelitis, the 
pentavalent (DPT-HepB+Hib) and the pneumo-13 were vaccines 
mostly administered. Apart from the intervention there was no 
statistical significant difference between the two groups concerning 
the sex and the age of children. Table 1 shows the sex, age and 
vaccine administered to participants by study groups. 1192 doses of 
vaccines were administered to 471 children. 
  
Outcomes and risk estimations 
  
For one month of follow-up, a total of 20(4.2%) AEFI have been 
detected and reported spontaneously, 19 in interventional group 
and 01in the control group. The reporting rate in the interventional 
group (8.1%/month) was significantly higher than the rate in the 
control group (0.4%/month), [RR = 18.9; CI 95 (2.5; 140.0) 
(P=0.0004)] .The attributable risk was 7.6% and the attributable 
fraction 0.94. Nine (45%) of AEFI were local reactions at the site of 





Our study suffers from bias and limits. The number of participants 
included in the survey was limited. The effect of telephone “beep” 
on the reporting rate of AEFI was gotten after a study on a small 
sample. It would be difficult to extrapolate this result to the region 
or the country. Our study suffers from bias and limits. The number 
of participants included in the survey was limited. Furthermore all 
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participants were recruited in the district hospital of Biyem-Assi-
Yaoundé. Is possible that the majority of participants were residents 
of an urban zone and therefore more accustomed to the use of the 
telephone “beep”. It could have introduced a selection bias because 
it would be difficult to say with certainty that rural zone residents 
will respond likely to those of the urban zones concerning the use of 
telephone “beep” for the surveillance of the AEFI. The reporting rate 
in the interventional group was significantly higher than the rate in 
the control group, (P=0.0004)]. The interest of this study is to 
identify an intervention as the use of the telephone “beep” to 
improve the community based AEFI reporting rate. In Cameroon, 
mobile phone operators cover the 10 regions of the country. “Mobile 
Telephone Network” (MTN) covers 84% of the population and 
orange 90% [21]. 
 
To the best of our knowledge, no study has been done on the 
reporting of AEFI based on the use of telephone “beep”. 
Nevertheless, other strategies tested us were revealed beneficial. A 
study using SMS for AEFI reporting was done in Cambodia. For 132 
SMS sent, AEFI reporting rate for 51 days was 17.4% [20]. This rate 
is superior to the one we got in our study concerning interventional 
group (8.4%). The difference in composition and in number of our 
samples could explain this difference. Another study testing 
automated text messages to monitor AEFI, produced results that 
are in line with the one obtained by this study. The proportion of 
respondent who reported possible AEFI was 11.3% [19]. But 
comparably to our study, there was no significant difference in 
proportion of reported AEFI between patients who replied by sms 
and those who did not respond by sms but were subsequently 
contacted by a telephone. Mobile phone based tools like sms have 
the capacity to complement existing passive reporting systems but 
the implication of a cost could be a barrier to reporting compared to 
our strategy. The absence of a control group during sms studies 
also show limits in proving the contribution of sms to improve rate 
of AEFI reporting, which was taken into account in our study. 
Another strategy was tested in Cameroon, concerning the effect of 
supervision on reporting rate. Supervision was more effective than 
sms or routine surveillance activities in improving AEFI reporting 
rate [17]. This strategy though beneficial, there is weakness of the 
health system in our context to conduct supervision. The use of 
telephone “bip” or signal easy to learn and to use or implement 
compared to supervision is an added value. Considering the limits of 
this study, it reveals that the use of telephone “bip” increases 
significantly community based AEFI reporting rate and can be used 
in Cameroon where the system of pharmaco vigilance needs an 
improvement. This strategy, free of charge, easy to use and to 
learn, simple compared to other strategies, could render this one 





The use of telephone “bip” increases significantly community based 
AEFI reporting rate,[RR = 18.9; CI95 (2.5; 140.0) (p=0.0004)]. This 
strategy could be tested to a larger scale and recommended as a 
surveillance tool of AEFI and adverse effects of drugs on 
Cameroonian market and why not apply for surveillance of 
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Table 1: Sex, age and vaccines administered to participants by 
study group 
Figure 1: Participants flow diagram at district hospital of Biyem-
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Table 1: Sex, age and vaccine administered to participants by study groups 
Caracteristic   Beep Group Non- beep Group P value 
  E E (n)    P (%) E (n) P (%)   
Sex Male 118 50.0 126 53.6 0.43 
Female 118 50.0 109 46.4 0.43 
Age group(in 
weeks) 
< 1 40 16.9 43 18.3 0.70 
[2-6] 55 23.3 45 19.1 0.20 
[7-10] 45 19.1 42 17.9 0.64 
[11-14] 37 15.7 51 21.1 0.09 
[15-52] 45 19.1 48 20.4 0.71 
> 52 14 5.9 06 2.6 0.06 
Vaccine BCG 40 16.9 46 19.6 0.60 
OPV 177 75 180 76.9 0.62 
PENTA 137 58.1 135 57.4 0.89 
Pneumo 136 57.6 135 57.4 0.96 
MV 45 19.1 48 20.4 0.71 
YFV 45 19.1 48 20.4 0.71 
BCG: Bacille de Calmette et Guérin - E: Effectif - P: percentage - OPV: 386 Oral Poliomyelitis 
Vaccine- PENTA: Diphteria, pertusis, Tetanus, Hepatitis B, Haemophilus- YFV: Yellow fever vaccine - 
MV: Measles Vaccine 
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Figure 1: Participants flow diagram at district hospital of Biyem-Assi (Cameroon), from December 2013 
to February 2014 
 
